Covered recipient · General Payments record
ROHIT LOOMBA
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$59,929.28
51 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $39,140.18 | 16 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,200.00 | 2 |
| Travel and Lodging | $3,031.13 | 7 |
| Honoraria | $2,400.00 | 1 |
| Food and Beverage | $2,157.97 | 25 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $16,496.07 | 9 |
| Kowa Research Institute, Inc. | $12,895.08 | 10 |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,712.32 | 6 |
| Eli Lilly and Company | $7,200.00 | 7 |
| Novo Nordisk Inc | $6,303.21 | 3 |
| GENZYME CORPORATION | $3,108.25 | 2 |
| BioMarin Pharmaceutical Inc. | $2,967.18 | 1 |
| Boehringer Ingelheim International GmbH | $650.00 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $549.96 | 4 |
| Novo Nordisk AS | $387.50 | 1 |
| AstraZeneca Pharmaceuticals LP | $135.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $122.16 | 1 |
| Amgen Inc. | $121.37 | 1 |
| Lilly USA, LLC | $113.73 | 1 |
| Aurinia Pharma U.S., Inc. | $105.60 | 1 |
| Boston Scientific Corporation | $35.34 | 1 |
| FUJIFILM Healthcare Americas Corporation | $26.51 | 1 |
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROHIT LOOMBA
NPI 1578593521 · CMS profile ID 920380
Allopathic & Osteopathic Physicians / Internal Medicine
LA JOLLA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROHIT LOOMBA, NPI 1578593521, CMS profile ID 920380. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ROHIT LOOMBA, NPI 1578593521, CMS profile ID 920380. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ROHIT LOOMBA, NPI 1578593521, CMS profile ID 920380, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
51 matching records · $59,929.28 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–51 of 51.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Kowa Research Institute, Inc. | $2,100.00 | 01/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1075874083 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $133,865.00 | 1 |
| PY2025 | Principal investigator | $349,886.65 | 121 |
| PY2024 | Principal investigator | $346,213.92 | 74 |
| PY2023 | Principal investigator | $6,388,539.71 | 23 |
| PY2022 | Recipient | $412.01 | 3 |
| PY2022 | Principal investigator | $931,768.05 | 80 |
| PY2021 | Recipient | $3,873.00 | 2 |
| PY2021 | Principal investigator | $911,669.69 | 75 |
| PY2020 | Recipient | $145.50 | 1 |
| PY2020 | Principal investigator | $4,095,425.70 | 75 |
| PY2019 | Recipient | $705.39 | 1 |
| PY2019 | Principal investigator | $1,116,412.10 | 89 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
122 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,558.08 | 11/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253121 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,560.00 | 11/18/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252703 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $585.00 | 11/17/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252670 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $1,713.04 | 11/14/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580229 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $4,315.85 | 11/14/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580231 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $455.00 | 11/14/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270546 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $962.00 | 11/07/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270528 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 11/05/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270524 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 10/29/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270518 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 10/29/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270520 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $332.50 | 10/22/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580227 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $332.50 | 10/22/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223270510 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 10/17/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270508 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $682.50 | 10/03/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270502 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,108.00 | 10/01/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270480 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $227.50 | 10/01/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270482 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $332.50 | 09/24/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580215 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $332.50 | 09/24/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580217 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $2,194.50 | 09/24/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580219 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $3,426.08 | 09/24/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580221 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $399.00 | 09/24/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580223 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $259.35 | 09/24/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580225 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 09/19/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 09/19/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270456 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 09/19/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270458 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 09/19/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270460 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,558.50 | 09/05/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185538865 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 08/27/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270374 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,970.00 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249209 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,150.50 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249212 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,150.50 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249217 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,970.00 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249221 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,970.00 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249226 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,150.50 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249229 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,800.00 | 08/26/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249234 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $455.00 | 08/22/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270370 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300.00 | 08/06/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270342 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $455.00 | 08/06/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270344 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 08/06/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270346 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $195.00 | 08/06/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270348 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,503.16 | 08/06/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270350 |
| Recipient | BioMarin Pharmaceutical Inc. | $133,865.00 | 07/25/2025 | Covered Recipient Physician | BMN-349 | No dispute reported | 06/30/2026 | 1248577924 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $6,783.00 | 07/23/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580197 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $4,592.49 | 07/18/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580191 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $332.50 | 07/18/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580193 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $6,783.00 | 07/18/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580195 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 07/18/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270326 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,189.50 | 07/02/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270308 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $390.00 | 06/19/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245854 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $9,123.14 | 06/16/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580213 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,787.50 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270248 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,593.60 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270250 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270252 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $455.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270254 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270256 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270258 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,262.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270260 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $988.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270262 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,120.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270264 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 06/13/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270266 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,329.23 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245418 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,350.00 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245422 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,300.00 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245425 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,625.00 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245429 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 06/06/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270242 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,341.00 | 05/28/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270220 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 05/28/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270222 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $191.91 | 05/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192159420 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $20,196.72 | 05/16/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580183 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $8,805.93 | 05/16/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580185 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $332.50 | 05/16/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580187 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $5,918.50 | 05/16/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580189 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 05/07/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270192 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,817.20 | 05/07/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270194 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $195.00 | 05/07/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270196 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $600.00 | 05/06/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243213 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,324.50 | 05/02/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension | No dispute reported | 06/30/2026 | 1185538863 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,077.95 | 05/01/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270190 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,647.83 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242798 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,451.50 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242576 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $1,667.82 | 04/16/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580211 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $910.00 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192159416 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,820.00 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192159429 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $910.00 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192160936 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $910.00 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192160950 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $455.00 | 04/02/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270142 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 04/01/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270130 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $104.00 | 04/01/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270140 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,170.00 | 03/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192159411 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,950.00 | 03/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192159424 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,900.00 | 03/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192160940 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $754.00 | 03/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192160945 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $988.00 | 03/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192160954 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,886.00 | 03/26/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270748 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 03/26/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270750 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $8,631.70 | 03/14/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580209 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $227.50 | 03/14/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270734 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 03/14/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270736 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,262.00 | 03/14/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270738 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,170.00 | 03/14/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270740 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,365.00 | 03/14/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270742 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,799.62 | 03/12/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270732 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 03/03/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270730 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 02/21/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270726 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,543.30 | 02/21/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270728 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $16,465.40 | 02/20/2025 | Non-covered Recipient Entity The Regents of the University of California | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171434 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $42,791.42 | 02/19/2025 | Non-covered Recipient Entity The Regents of the University of California | BMN 349-102 | No dispute reported | 06/30/2026 | 1248580207 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,295.66 | 02/17/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239851 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,412.12 | 02/12/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270724 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,329.23 | 01/24/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238791 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 01/24/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270712 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 01/22/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270708 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $390.00 | 01/22/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1223270710 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $325.00 | 01/15/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270706 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,350.70 | 01/10/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270698 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 01/10/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270700 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,985.50 | 01/10/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270702 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 01/10/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270704 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,381.08 | 01/03/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237927 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,190.54 | 01/03/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237931 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,000.00 | 01/03/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN DIEGO | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237935 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 01/03/2025 | Covered Recipient Teaching Hospital UCSD MEDICAL CENTER | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223270696 |